Oscar Zaragoza-García, Olivia Briceño, José Rafael Villafan-Bernal, Ilse Adriana Gutiérrez-Pérez, Héctor Ugo Rojas-Delgado, Gustavo Adolfo Alonso-Silverio, Antonio Alarcón-Paredes, José Eduardo Navarro-Zarza, Cristina Morales-Martínez, Rubén Rodríguez-García, Iris Paola Guzmán-Guzmán
{"title":"女性类风湿性关节炎患者的 sCD163 水平:与心血管风险指标的关系。","authors":"Oscar Zaragoza-García, Olivia Briceño, José Rafael Villafan-Bernal, Ilse Adriana Gutiérrez-Pérez, Héctor Ugo Rojas-Delgado, Gustavo Adolfo Alonso-Silverio, Antonio Alarcón-Paredes, José Eduardo Navarro-Zarza, Cristina Morales-Martínez, Rubén Rodríguez-García, Iris Paola Guzmán-Guzmán","doi":"10.1016/j.arteri.2024.04.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>The soluble scavenger receptor differentiation antigen 163 (sCD163), a monocyte/macrophage activation marker, is related to cardiovascular mortality in the general population. This study aimed to evaluate their relationship between serum levels of sCD163 with cardiovascular risk indicators in rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>A cross-sectional study was performed on 80 women diagnosed with RA. The cardiovascular risks were determined using the lipid profile, metabolic syndrome, and QRISK3 calculator. For the assessment of RA activity, we evaluated the DAS28 with erythrocyte sedimentation rate (DAS28-ESR). The serum levels of sCD163 were determined by the ELISA method. Logistic regression models and receiver operating characteristics (ROC) curve were used to assess the association and predictive value of sCD163 with cardiovascular risk in RA patients.</p><p><strong>Results: </strong>Levels of sCD163 were significantly higher in RA patients with high sensitivity protein C-reactive to HDL-c ratio (CHR)≥0.121 (p=0.003), total cholesterol/HDL-c ratio>7% (p=0.004), LDL-c/HDL-c ratio>3% (p=0.035), atherogenic index of plasma>0.21 (p=0.004), cardiometabolic index (CMI)≥1.70 (p=0.005), and high DAS28-ESR (p=0.004). In multivariate analysis, levels of sCD163≥1107.3ng/mL were associated with CHR≥0.121 (OR=3.43, p=0.020), CMI≥1.70 (OR=4.25, p=0.005), total cholesterol/HDL-c ratio>7% (OR=6.63, p=0.044), as well as with DAS28-ESR>3.2 (OR=8.10, p=0.008). Moreover, levels of sCD163 predicted CHR≥0.121 (AUC=0.701), cholesterol total/HDL ratio>7% (AUC=0.764), and DAS28-ESR>3.2 (AUC=0.720).</p><p><strong>Conclusion: </strong>Serum levels of sCD163 could be considered a surrogate of cardiovascular risk and clinical activity in RA.</p>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Levels of sCD163 in women rheumatoid arthritis: Relationship with cardiovascular risk markers.\",\"authors\":\"Oscar Zaragoza-García, Olivia Briceño, José Rafael Villafan-Bernal, Ilse Adriana Gutiérrez-Pérez, Héctor Ugo Rojas-Delgado, Gustavo Adolfo Alonso-Silverio, Antonio Alarcón-Paredes, José Eduardo Navarro-Zarza, Cristina Morales-Martínez, Rubén Rodríguez-García, Iris Paola Guzmán-Guzmán\",\"doi\":\"10.1016/j.arteri.2024.04.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>The soluble scavenger receptor differentiation antigen 163 (sCD163), a monocyte/macrophage activation marker, is related to cardiovascular mortality in the general population. This study aimed to evaluate their relationship between serum levels of sCD163 with cardiovascular risk indicators in rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>A cross-sectional study was performed on 80 women diagnosed with RA. The cardiovascular risks were determined using the lipid profile, metabolic syndrome, and QRISK3 calculator. For the assessment of RA activity, we evaluated the DAS28 with erythrocyte sedimentation rate (DAS28-ESR). The serum levels of sCD163 were determined by the ELISA method. Logistic regression models and receiver operating characteristics (ROC) curve were used to assess the association and predictive value of sCD163 with cardiovascular risk in RA patients.</p><p><strong>Results: </strong>Levels of sCD163 were significantly higher in RA patients with high sensitivity protein C-reactive to HDL-c ratio (CHR)≥0.121 (p=0.003), total cholesterol/HDL-c ratio>7% (p=0.004), LDL-c/HDL-c ratio>3% (p=0.035), atherogenic index of plasma>0.21 (p=0.004), cardiometabolic index (CMI)≥1.70 (p=0.005), and high DAS28-ESR (p=0.004). In multivariate analysis, levels of sCD163≥1107.3ng/mL were associated with CHR≥0.121 (OR=3.43, p=0.020), CMI≥1.70 (OR=4.25, p=0.005), total cholesterol/HDL-c ratio>7% (OR=6.63, p=0.044), as well as with DAS28-ESR>3.2 (OR=8.10, p=0.008). Moreover, levels of sCD163 predicted CHR≥0.121 (AUC=0.701), cholesterol total/HDL ratio>7% (AUC=0.764), and DAS28-ESR>3.2 (AUC=0.720).</p><p><strong>Conclusion: </strong>Serum levels of sCD163 could be considered a surrogate of cardiovascular risk and clinical activity in RA.</p>\",\"PeriodicalId\":45230,\"journal\":{\"name\":\"Clinica e Investigacion en Arteriosclerosis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica e Investigacion en Arteriosclerosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.arteri.2024.04.002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica e Investigacion en Arteriosclerosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.arteri.2024.04.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
摘要
目的:可溶性清道夫受体分化抗原163(sCD163)是一种单核细胞/巨噬细胞活化标志物,与普通人群的心血管死亡率有关。本研究旨在评估类风湿关节炎(RA)患者血清中 sCD163 水平与心血管风险指标之间的关系:方法:对 80 名确诊为 RA 的女性进行了横断面研究。方法:我们对 80 名确诊为 RA 的女性进行了横断面研究,并使用血脂概况、代谢综合征和 QRISK3 计算器确定了心血管风险。为了评估 RA 的活动性,我们评估了 DAS28 和红细胞沉降率(DAS28-ESR)。血清中 sCD163 的水平采用 ELISA 方法测定。我们使用逻辑回归模型和接收器操作特征曲线(ROC)评估了sCD163与RA患者心血管风险的相关性和预测价值:结果:高敏感蛋白 C 反应与高密度脂蛋白胆固醇比值(CHR)≥0.121(P=0.003)、总胆固醇/高密度脂蛋白胆固醇比值>7%(P=0.004)、LDL-c/HDL-c 比值>3%(p=0.035)、血浆致动脉粥样硬化指数>0.21(p=0.004)、心脏代谢指数(CMI)≥1.70(p=0.005)、DAS28-ESR 偏高(p=0.004)。在多变量分析中,sCD163水平≥1107.3ng/mL与CHR≥0.121(OR=3.43,p=0.020)、CMI≥1.70(OR=4.25,p=0.005)、总胆固醇/HDL-c比值>7%(OR=6.63,p=0.044)以及DAS28-ESR>3.2(OR=8.10,p=0.008)相关。此外,sCD163水平可预测CHR≥0.121(AUC=0.701)、胆固醇总/高密度脂蛋白比率>7%(AUC=0.764)和DAS28-ESR>3.2(AUC=0.720):结论:血清sCD163水平可被视为RA心血管风险和临床活动的替代指标。
Levels of sCD163 in women rheumatoid arthritis: Relationship with cardiovascular risk markers.
Aim: The soluble scavenger receptor differentiation antigen 163 (sCD163), a monocyte/macrophage activation marker, is related to cardiovascular mortality in the general population. This study aimed to evaluate their relationship between serum levels of sCD163 with cardiovascular risk indicators in rheumatoid arthritis (RA).
Methods: A cross-sectional study was performed on 80 women diagnosed with RA. The cardiovascular risks were determined using the lipid profile, metabolic syndrome, and QRISK3 calculator. For the assessment of RA activity, we evaluated the DAS28 with erythrocyte sedimentation rate (DAS28-ESR). The serum levels of sCD163 were determined by the ELISA method. Logistic regression models and receiver operating characteristics (ROC) curve were used to assess the association and predictive value of sCD163 with cardiovascular risk in RA patients.
Results: Levels of sCD163 were significantly higher in RA patients with high sensitivity protein C-reactive to HDL-c ratio (CHR)≥0.121 (p=0.003), total cholesterol/HDL-c ratio>7% (p=0.004), LDL-c/HDL-c ratio>3% (p=0.035), atherogenic index of plasma>0.21 (p=0.004), cardiometabolic index (CMI)≥1.70 (p=0.005), and high DAS28-ESR (p=0.004). In multivariate analysis, levels of sCD163≥1107.3ng/mL were associated with CHR≥0.121 (OR=3.43, p=0.020), CMI≥1.70 (OR=4.25, p=0.005), total cholesterol/HDL-c ratio>7% (OR=6.63, p=0.044), as well as with DAS28-ESR>3.2 (OR=8.10, p=0.008). Moreover, levels of sCD163 predicted CHR≥0.121 (AUC=0.701), cholesterol total/HDL ratio>7% (AUC=0.764), and DAS28-ESR>3.2 (AUC=0.720).
Conclusion: Serum levels of sCD163 could be considered a surrogate of cardiovascular risk and clinical activity in RA.
期刊介绍:
La publicación idónea para acceder tanto a los últimos originales de investigación como a formación médica continuada sobre la arteriosclerosis y su etiología, epidemiología, fisiopatología, diagnóstico y tratamiento. Además, es la publicación oficial de la Sociedad Española de Arteriosclerosis.